Insider Selling: Medpace (NASDAQ:MEDP) CFO Sells 3,000 Shares of Stock

by · The Cerbat Gem

Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CFO Kevin Brady sold 3,000 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the transaction, the chief financial officer owned 6,000 shares in the company, valued at $3,542,100. The trade was a 33.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Medpace Stock Performance

MEDP stock traded down $6.68 during trading on Tuesday, hitting $611.81. The stock had a trading volume of 352,084 shares, compared to its average volume of 412,556. The stock has a market cap of $17.23 billion, a price-to-earnings ratio of 42.78, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42. The company’s 50 day moving average price is $551.90 and its two-hundred day moving average price is $436.91. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $626.26.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. Medpace’s revenue was up 23.7% on a year-over-year basis. During the same quarter last year, the firm posted $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medpace

Hedge funds have recently added to or reduced their stakes in the stock. Quent Capital LLC acquired a new position in Medpace during the 3rd quarter valued at about $25,000. Optiver Holding B.V. bought a new stake in shares of Medpace during the third quarter worth approximately $27,000. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the period. Brooklyn Investment Group lifted its holdings in Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after buying an additional 71 shares during the period. Finally, Quarry LP bought a new position in Medpace in the third quarter valued at approximately $35,000. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Jefferies Financial Group boosted their price objective on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research report on Tuesday, September 9th. Cowen reissued a “sell” rating on shares of Medpace in a report on Friday, October 24th. Mizuho increased their price target on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. Finally, TD Cowen boosted their price objective on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have assigned a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus target price of $487.18.

Get Our Latest Report on Medpace

About Medpace

(Get Free Report)

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Further Reading